Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXELIXIS, INC. Director's Dealing 2023

Aug 8, 2023

30561_dirs_2023-08-07_74a2f74a-18b3-4bce-bf87-7fd06c4f6dd5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2023-08-03

Reporting Person: Senner Christopher J. (EVP and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-08-03 Common Stock M 60000 $14.74 Acquired 631631 Direct
2023-08-03 Common Stock S 60000 $20.51 Disposed 571631 Direct
2023-08-04 Common Stock M 60000 $14.74 Acquired 631631 Direct
2023-08-04 Common Stock S 60000 $20.68 Disposed 571631 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-08-03 Option (right to buy) $14.74 M 60000 Disposed 2023-09-21 Common Stock (60000) Direct
2023-08-04 Option (right to buy) $14.74 M 60000 Disposed 2023-09-21 Common Stock (60000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 2723 Indirect

Footnotes

F1: Includes 190,763 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $20.50 to $20.60. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4.

F3: Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of August 2, 2023.

F4: The option, representing the right to purchase a total of 120,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 22, 2020.